A review of AbobotulinumtoxinA (Dysport).

Z. Paul Lorenc, Jeffrey M. Kenkel, Steven Fagien, Haideh Hirmand, Mark S. Nestor, Anthony P. Sclafani, Jonathan M. Sykes, Heidi A. Waldorf

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.

Original languageEnglish (US)
Pages (from-to)13S-7S
JournalUnknown Journal
Issue number1 Suppl
StatePublished - Mar 2013

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'A review of AbobotulinumtoxinA (Dysport).'. Together they form a unique fingerprint.

Cite this